BRPI0616600A2 - linhagens de célula hospedeira para produção de região constante de anticorpo com função efetora aumentada - Google Patents

linhagens de célula hospedeira para produção de região constante de anticorpo com função efetora aumentada Download PDF

Info

Publication number
BRPI0616600A2
BRPI0616600A2 BRPI0616600-8A BRPI0616600A BRPI0616600A2 BR PI0616600 A2 BRPI0616600 A2 BR PI0616600A2 BR PI0616600 A BRPI0616600 A BR PI0616600A BR PI0616600 A2 BRPI0616600 A2 BR PI0616600A2
Authority
BR
Brazil
Prior art keywords
antibody
cell line
cell
cells
human
Prior art date
Application number
BRPI0616600-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Haimanti Dorai
Yun Seung Kyung
Bernard Scallon
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of BRPI0616600A2 publication Critical patent/BRPI0616600A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
BRPI0616600-8A 2005-08-31 2006-08-31 linhagens de célula hospedeira para produção de região constante de anticorpo com função efetora aumentada BRPI0616600A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US71305505P 2005-08-31 2005-08-31
US71285805P 2005-08-31 2005-08-31
US60/713,055 2005-08-31
US60/712,858 2005-08-31
PCT/US2006/034382 WO2007028106A2 (en) 2005-08-31 2006-08-31 Host cell lines for production of antibody constant region with enhanced effector function

Publications (1)

Publication Number Publication Date
BRPI0616600A2 true BRPI0616600A2 (pt) 2011-06-28

Family

ID=37809622

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0616600-8A BRPI0616600A2 (pt) 2005-08-31 2006-08-31 linhagens de célula hospedeira para produção de região constante de anticorpo com função efetora aumentada

Country Status (9)

Country Link
US (1) US20090214528A1 (enExample)
EP (1) EP1937313A4 (enExample)
JP (1) JP2009508476A (enExample)
KR (1) KR20080048505A (enExample)
AU (1) AU2006287224A1 (enExample)
BR (1) BRPI0616600A2 (enExample)
CA (1) CA2621236A1 (enExample)
MX (1) MX2008003054A (enExample)
WO (1) WO2007028106A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP2434894B1 (en) * 2009-05-29 2016-08-31 Novartis AG Methods of administration of thrombopoietin agonist compounds
EP4328305A3 (en) * 2009-12-18 2024-08-14 CSL Ltd. Method of purifying polypeptides
GB201003701D0 (en) * 2010-03-05 2010-04-21 Cilian Ag System for the expression of a protein
WO2013087914A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
BR112015013105B1 (pt) 2012-12-05 2022-02-08 Alnylam Pharmaceuticals, Inc Agente de rnai de fita dupla capaz de inibir a expressão de pcsk9, seus usos, composição farmacêutica e método de inibição da expressão de pcsk9 em uma célula in vitro
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
US8956830B2 (en) * 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
KR20170010003A (ko) * 2014-05-27 2017-01-25 아카데미아 시니카 박테로이드 기원의 푸코시다제 및 이의 사용 방법
EP3340994A1 (en) * 2015-08-25 2018-07-04 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder
US10465003B2 (en) * 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
CN110234351A (zh) * 2017-01-30 2019-09-13 詹森生物科技公司 用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法
KR20240038148A (ko) * 2017-02-07 2024-03-22 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
KR102323342B1 (ko) 2019-04-26 2021-11-08 주식회사 와이바이오로직스 IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체
AU2020267953A1 (en) * 2019-05-08 2021-11-18 Novartis Ag Anti-CD40 antibodies for use in treatment of T1DM and insulitis
EP3972690A4 (en) * 2019-05-23 2023-07-05 Janssen Biotech, Inc. METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA
CA3183927A1 (en) 2020-05-21 2021-11-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1079704A (en) 1912-06-19 1913-11-25 Dallas C Hathaway Combination tire valve-stem and pressure-gage.
DE3167442D1 (en) 1980-07-07 1985-01-10 Nat Res Dev Improvements in or relating to cell lines
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4816597A (en) * 1983-10-02 1989-03-28 New Jersey Institute Of Technology Dental restorative materials based upon blocked isocyanates
GB8421551D0 (en) 1984-08-24 1984-09-26 Ici Plc Water-soluble dye
EP0833911B1 (en) 1995-06-07 2004-05-12 Ortho Pharmaceutical Corporation Cdr-grafted anti-tissue factor antibodies and methods of use thereof
AU736993B2 (en) * 1997-01-16 2001-08-09 Novo Nordisk A/S Practical in vitro sialylation of recombinant glycoproteins
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
EP2275540B1 (en) * 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
DE60230858D1 (de) 2001-02-15 2009-03-05 Centocor Inc Chemisch definiertes medium für kultivierte säugerzellen
EP1498490A4 (en) * 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
KR20050000380A (ko) * 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
US7605235B2 (en) * 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
JP2006526641A (ja) * 2003-05-30 2006-11-24 セントカー・インコーポレーテツド 抗−組織因子抗体を用いる腫瘍成長を抑制する方法

Also Published As

Publication number Publication date
US20090214528A1 (en) 2009-08-27
MX2008003054A (es) 2008-03-25
EP1937313A4 (en) 2010-03-24
AU2006287224A1 (en) 2007-03-08
WO2007028106A2 (en) 2007-03-08
CA2621236A1 (en) 2007-03-08
KR20080048505A (ko) 2008-06-02
WO2007028106A3 (en) 2009-06-11
EP1937313A2 (en) 2008-07-02
JP2009508476A (ja) 2009-03-05

Similar Documents

Publication Publication Date Title
US12559555B2 (en) Anti-LILRB4 antibodies and derivative products
JP6840908B1 (ja) エフェクター機能が除去されたＩｇＧ１ Ｆｃ変異体
CN113583131B (zh) 抗tigit抗体
JP4351674B2 (ja) 免疫グロブリン変異体とその使用法およびその使用
CA2674239C (en) Methods and vectors for generating asialylated immunoglobulins
CN102822201B (zh) 抗her3抗体及其用途
US20090214528A1 (en) Host cell lines for production of antibody constant region with enhanced effector function
EP4214240B1 (en) Anti-ccr8 antibodies
TW201934580A (zh) 對cd70具特異性抗體及其用途
MX2011000616A (es) Composiciones y metodos de uso para anticuerpos terapeuticos.
PT1896071E (pt) Métodos e composições com melhorias na atividade terapêutica
WO2003084570A1 (en) DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
WO2023020625A1 (zh) 包含抗TIGIT抗体和TGF-βR的融合蛋白、其药物组合物及用途
US20230400467A1 (en) Pvrl2 and/or pvrig as biomarkers for treatment
CN101627111A (zh) 用于生产具有增强的效应子功能的抗体恒定区的宿主细胞系
US20250179175A1 (en) Anti-cd160 transmembrane isoform antibodies
HK40100657B (en) Anti-ccr8 antibodies
HK40100657A (en) Anti-ccr8 antibodies
CN117567612A (zh) 一种cldn18.2抗体及其应用
HK40093865A (en) Compositions and methods of treating lupus nephritis

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: JOHNSON AND JOHNSON (US)

Free format text: TRANSFERIDO DE: CENTOCOR, INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal: dismissal of application maintained